It is very uncertain whether highest changes colorectal cancer risk No. of participants: 712,746 (6 observational… compared with lowest selenium exposure (very low certainty).
It is very uncertain whether highest changes lung cancer risk No. of participants: 371,067 (11 observational… compared with lowest selenium exposure (very low certainty).
It is very uncertain whether highest changes breast cancer risk (women) No. of participants: 169,028 (8… compared with lowest selenium exposure (very low certainty).
It is very uncertain whether highest changes bladder cancer risk No. of participants: 279,100 (5 observational… compared with lowest selenium exposure (very low certainty).
It is very uncertain whether highest changes prostate cancer risk No. of participants: 576,667 (21 observational… compared with lowest selenium exposure (very low certainty).
Highest showed no clear difference in cancer mortality risk No. of participants: 17,448 (1 RCT) compared with lowest selenium exposure (high certainty).
Highest showed no clear difference in colorectal cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
Highest showed no clear difference in non‐melanoma skin cancer risk No. of participants: 2027 (2 RCTs) compared with lowest selenium exposure (moderate certainty).
Highest showed no clear difference in lung cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
Highest showed no clear difference in breast cancer risk No. of participants: 802 (1 RCT) compared with lowest selenium exposure (moderate certainty).
Highest showed no clear difference in bladder cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
Highest showed no clear difference in prostate cancer risk No. of participants: 18,942 (4 RCTs) compared with lowest selenium exposure (high certainty).
It is very uncertain whether highest changes any cancer risk No. of participants: 76,239 (7 observational studies) compared with lowest selenium exposure (very low certainty).
The review found no eligible studies for this question.
Summary of findings: Higher bladder volume showed no clear difference in acute and late GI toxicity (grade 2+) compared with lower bladder volume (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).